Benzinga

Benzinga

Benzinga

martedì, agosto 25

Senti Biosciences Holdings Inc

SNTINASDAQ
Trade with Public
Trade with Public
$0.3780
-0.0106-2.73%
In chiusura: Aug 24, 5:00 PM EST
$0.3571
-0.0209-5.53%
Post-mercato: 7:22 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaRapporto azionario

Senti Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Senti Biosciences (SNTI).

Price Target Range — 6 Quarters

Analyst Consensus — 4 Analysts

4Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$11Upside to Avg. PT+3050.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 15, 2026Chardan CapitalGeulah LivshitsPT RaiseBuy$11→$12
Mar 30, 2026Chardan CapitalGeulah LivshitsPT CutBuy$13→$11
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $11 to $12.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $13 to $11.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $12 to $13.
Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

Leerink Partners analyst Jeffrey La Rosa initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Outperform rating and announces Price Target of $6.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and maintains $12 price target.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved